Data-Driven Insights

Specialty Pharmacy Status/Sub-Status Analysis Highlights Inconsistencies in Data Quality

March 21, 2017   |   Brandon Underwood

A Sneak Peek at our Upcoming Benchmark Report Manufacturers contract with specialty pharmacies to provide a variety of services. One of these contracted services is data reporting on status/sub-status combinations. These status/sub-status combinations can be mapped to explain in great detail the steps taken by patient, provider, and pharmacist from therapy initiation through therapy completion/cancellation/discontinuation – a process known as the patient journey. In the course of developing Specialty Analytics, a joint offering of IntegriChain and ProMetrics, we grew to suspect that the quality and granularity of status/sub-status data being reported to manufacturers varied considerably by brand, therapeutic category, specialty…

Read More

Tags: , , ,

Leveraging Scorecard Analytics to Optimize Changes to DSAs

June 2, 2016   |   Sunay Shah

In my last post, I explored how IntegriChain Scorecard Analytics can be used to validate whether the implementation of Distribution Service Agreements (DSAs) drives channel performance. In this post, we will deep dive with a step-by-step approach outlining how Scorecard Analytics can be leverage to optimize changes to DSAs. First, let’s look at the metrics. DSA metrics come in two basic flavors – performance and data transmission The performance metrics are typically composed of a service level metric, purchase stability (or demand variability) metric, and an inventory level metric. The data transmission metrics are typically composed of data delivery timeliness, completeness, and…

Read More

Tags: , , ,

Trends in Specialty Pharmacy Channel Design – Takeaways from Asembia Specialty Pharmacy Summit

May 27, 2016   |   Colleen Hallett

The Asembia (formerly known as Armada) Specialty Pharmacy Summit is fast becoming the pharmaceutical industry’s most important meeting. This year’s Las Vegas show boasted a record attendance of nearly 5,000 pharmaceutical manufacturers, specialty pharmacies, payers, and solution vendors. As new therapies trend more and more towards high price, niche, or patient-tailored treatments often requiring special handling, this surge of interest in all things specialty pharmacy is no surprise. The enormous rise in specialty brand launches has changed the traditional channel distribution model. Life sciences distribution channels have become much more complicated, and this has led to an increase in the number…

Read More

IntegriChain Continues to Lead in Automated, End-to-End Management of Pharma Distribution Service Agreements

April 6, 2016   |   Sunay Shah

Distribution Service Agreements (DSAs) have continued to evolve over recent years especially as they relate to how they evaluate channel performance. For the most part, manufacturers structure the agreements to ensure trade partners effectively and efficiently fulfill downstream orders, manage volatility of orders, maintain appropriate inventory level (as defined by manufacturer), and transmit data to manufacturers. As the industry matures in how DSAs are structured, we are seeing trends of new concepts such as misses being incorporated into agreements. However, what is very interesting is how much the industry has validated the efficacy of DSAs. Even as the agreements are…

Read More

Tags: , , ,

867 Master Data and Channel Analytics Has Emerged as the Best Solution for 5i Products Under the Final AMP Rule

March 2, 2016   |   Dave Weiss

By now, government price departments are well underway towards implementing the Final Average Manufacturer Price (AMP) Rule recently issued by the Center of Medicare and Medicaid Services (CMS). AMP is the average manufacturer price paid by retail community pharmacies (RCP). One of the key provisions of the sub-regulatory guidance is related to “5i” drugs (i.e., infused, injected, implanted, inhaled, or instilled drugs) that are drugs that are “not generally dispensed“ (NGD) in retail pharmacies but rather at infusion centers, specialty pharmacies, and so on. Even though 5i drugs are not sold into retail, they still require an AMP for other…

Read More

Tags: , , ,

IntegriChain and Accel-KKR Share Vision for Serving Evolving Channel Analytic Needs of Life Sciences Companies

March 1, 2016   |   Kevin Leininger

Today we announced an equity partnership with Accel-KKR (AKKR) that is very exciting both for IntegriChain and our customers. Both IntegriChain and AKKR share a singular vision to service underserved constituencies in the life sciences industry. Life sciences companies are facing a rapidly evolving marketplace driven by changes across the entire healthcare ecosystem from providers to payers and distribution platforms. Navigating this requires life sciences companies to completely rethink the way they advance and support the patient journey. The days of primary care physicians and retail pharmacies serving branded, pill-based prescription products shipped once per week from wholesalers across the…

Read More

Tags: ,

IntegriChain at Philly CODEFEST 2016

February 25, 2016   |   Miguel Guerreiro

Drexel University’s College of Computing & Informatics hosted its fourth Philly CODEFEST, a two-day coding competition to transform data into real-world solutions. IntegriChain was a huge part of the event by providing judges and mentors and by hosting a workshop to talk to the students about what technology companies are looking for in co-ops and employees. This is just another instance of our continued effort to promote Philadelphia-area technology, which is really starting to expand in the region. We would like to congratulate everyone who won a prize including team Good Civilianship, who won the Grand Prize, the Student Grand Prize, and…

Read More

Tags: , , ,

Data… Data… Data…

January 29, 2016   |   Sunay Shah

Everywhere you look, data is being collected and stored in an electronic format. From electronic medical records to the Internet of things, data collection is omnipresent; however, trying to figure out how to extract the maximum value from all of the collected data is a continuous process. Most industries–including consumer marketing, finance, healthcare, and technology–are seeing a revolution in how they analyze data as the amount of data they have at their disposal continues to increase by orders of magnitude. So much so that overall, 90% of the world’s data has been collected in the past two years.* Focusing on…

Read More

Tags: , , ,

Troubling Results of HRSA’s 2015 Program Integrity Audits Posted on November 25

December 16, 2015   |   Dave Weiss

While we applaud the Health Resources and Services Administration (HRSA) for its efforts to create more transparency in the 340B program through its proposed guidance and program integrity initiative, a quick inspection of the 2015 audit results posted on the Office of Pharmacy Affairs (OPA) website is deeply concerning. As part of this report, HRSA audited 137 covered entities in 2015, which was a 30% increase above 2014. If the results are extrapolated to the universe of 30,000+ covered entities (and their associated contract pharmacies) then the level of potential abuse is far worse than even its harshest critics could…

Read More

Tags: ,

Renewed Emphasis on Driving the Retail Pharmacy Channel

December 2, 2015   |   Josh Halpern

You might have noticed that we recently announced the release of a new set of channel visualizations focused on the retail pharmacy. In an era when specialty pharmacy so dominates our industry’s headlines, you might be surprised to learn that a growing number of our customers are turning renewed attention and resources to the retail pharmacy channel.  Manufacturers are examining retail pharmacy design and pharmacist engagement with a fresh eye, and some are finding attractive opportunities to improve the patient experience and maximize brand success. First a little history. Back in the 20th century, before the advent of script data, drug…

Read More

Tags: , ,